LentiBOOST Now Used In More Than 35 Cell Therapy Clinical Trials!
SIRION Biotech's LentiBOOST Lentiviral Transduction Reagent is used in an ever-increasing number of clinical trials and has been approved for use in at least 1 commercially available cell therapy. It is rapidly becoming the gold standard in the industry.
LentiBOOST is non-cytotoxic and can be applied to a wide range of clinically relevant cell types, including CD34+ hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), neuronal stem cells, primary T cells, hard-to-transduce murine T cells, NK cells, and fibroblasts. It is ideal for clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.
Find out more about LentiBOOST.